| Literature DB >> 30624522 |
Enrique Norero1, Catalina Vargas1, Pablo Achurra1, Marco Ceroni1, Ricardo Mejia1, Cristian Martinez1, Rodrigo Muñoz1, Paulina Gonzalez1, Alfonso Calvo1, Alfonso Díaz1.
Abstract
BACKGROUND: Laparoscopic gastrectomy has numerous perioperative advantages, but the long-term survival of patients after this procedure has been less studied. AIM: To compare survival, oncologic and perioperative outcomes between completely laparoscopic vs. open gastrectomy for early gastric cancer.Entities:
Mesh:
Year: 2019 PMID: 30624522 PMCID: PMC6323630 DOI: 10.1590/0102-672020180001e1413
Source DB: PubMed Journal: Arq Bras Cir Dig ISSN: 0102-6720
Patient demographics and surgery details
| Open gastrectomy l(n=66) | Laparoscopic gastrectomy (n=50) | p | |
| Age (years) | 69 (33-86) | 69 (38-85) | 0.618 |
| Sex (male) | 43 (65.2%) | 26 (52.0%) | 0.153 |
| BMI (kg/mt2) | 23.9 (19-38) | 26.5 (20-32) | 0.126 |
| ASA score | 0.173 | ||
| I | 14 (21.2%) | 17 (34.0%) | |
| II | 39 (59.1%) | 28 (56.0%) | |
| III | 13 (19.7%) | 5 (10.0%) | |
| Hypertension | 30 (45.5%) | 25 (50.0%) | 0.627 |
| Diabetes | 12 (18.2%) | 6 (12.0%) | 0.362 |
| Cardiac disease | 9 (13.6%) | 5 (10.0%) | 0.552 |
| Stroke | 4 (6.1%) | 2 (4.0%) | 0.479 |
| Pulmonary disease | 6 (9.1%) | 4 (8%) | 0.555 |
| Chronic liver disease | 2 (3.0%) | 1 (2.0%) | 0.604 |
| Previous laparotomy | 31 (50.8%) | 29 (58.0%) | 0.450 |
| Upper abdominal laparotomy | 20 (32.8%) | 16 (32.0%) | 0.930 |
| Tumour location | 0.572 | ||
| Superior | 23 (38.3%) | 17 (34.0%) | |
| Middle | 21 (35.0%) | 15 (30.0%) | |
| Inferior | 16 (26.7%) | 18 (36.0%) | |
| Gastrectomy type | 0.785 | ||
| Total | 36 (54.5%) | 26 (52.0%) | |
| Subtotal distal | 30 (45.5%) | 24 (48.0%) | |
| Lymph node dissection | 0.170 | ||
| D0 | 0 (0%) | 1 (2.0%) | |
| D1 | 8 (14.5%) | 3 (6.0%) | |
| D1 + | 12 (21.8%) | 18 (36.0%) | |
| D2 | 35 (63.6%) | 28 (56.0%) | |
| Subtotal gastrectomy reconstruction | 0.005 | ||
| Billroth I | 0 (0%) | 1 (4.8%) | |
| Billroth II | 16 (64.0%) | 4 (19.0%) | |
| Y Roux | 9 (36.0%) | 17 (76.2%) | |
| Operative time (min) | 240 (120-480) | 330 (210-510) | 0.0001 |
| Operative bleeding (cc) | 300 (50-800) | 110 (10-500) | 0.038 |
BMI=body mass index, ASA=American Society of Anaesthesiologists Physical Status Classification
Postoperative clinical outcome and complications
| Complications | Open gastrectomy l(n=66) | Laparoscopic gastrectomy (n=50) | p |
| Intrabdominal | 10 (15.2%) | 11 (22.0%) | 0.343 |
| EJ fistula | 2 (5.6%) | 3 (11.5%) | 0.346 |
| Duodenal fistula | 0 (0%) | 3 (6.0%) | 0.077 |
| Subphrenic abscess | 1 (1.5%) | 1 (2.0%) | 0.678 |
| EJ stenosis | 2 (5.6%) | 0 (0%) | 0.333 |
| Pancreatic fistula | 0 (0%) | 1 (0%) | 0.431 |
| Abdominal bleeding | 1 (1.5%) | 0 (0%) | 0.569 |
| Ileus | 1 (1.5%) | 0 (0%) | 0.569 |
| Delayed gastric emptying | 0 (0%) | 3 (12.5%) | 0.082 |
| Wound - Abdominal wall | 8 (12.1%) | 0 (0%) | 0.009 |
| Dehiscence | 5 (7.6%) | 0 (0%) | 0.056 |
| Surgical site infection | 3 (4.5%) | 0 (0%) | 0.181 |
| Medical | 11 (16.7%) | 4 (8.0%) | 0.136 |
| Respiratory | 6 (9.1%) | 0 (0%) | 0.031 |
| Pneumonia | 4 (6.1%) | 0 (0%) | 0.101 |
| Pleural effusion | 2 (3.0%) | 0 (0%) | 0.322 |
| Respiratory failure | 1 (1.5%) | 0 (%) | 0.569 |
| Arrhythmia | 2 (3.0%) | 0 (0%) | 0.322 |
| Pseudomembranous colitis1 (1.5%) | 1 (1.5%) | 2 (4.0%) | 0.396 |
| Urinary tract infection | 2 (3.0%) | 1 (2.0%) | 0.604 |
| Central catheter infection | 1 (1.5%) | 0 (0%) | 0.569 |
| Thromboembolic disease | 2 (3.0%) | 1 (2.0%) | 0.604 |
| Stroke | 1 (1.5%) | 0 (0%) | 0.569 |
| Morbidity | 27 (40.9%) | 14 (28.0%) | 0.150 |
| Reoperation | 3 (4.5%) | 2 (4%) | 0.630 |
| Morbidity Clavien ≥ 2 | 24 (36.4%) | 9 (18%) | 0.030 |
| Morbidity Clavien ≥ 3 | 9 (13.6%) | 2 (4.0%) | 0.072 |
| Mortality | 2 (3.0%) | 1 (2.0%) | 0.604 |
| Length of stay (days) | 9 (5-60) | 7 (4-37) | 0.017 |
| Readmission | 7 (10.6%) | 2 (4.0%) | 0.070 |
Pathologic staging, lymph node count and margin status
| Complications | Open gastrectomy l(n=66) | Laparoscopic gastrectomy (n=50) | p |
| T | 0.334 | ||
| T1a (mucosa) | 35 (53.0%) | 31 (62.0%) | |
| T1b (submucosa) | 31 (47.0%) | 19 (38.0%) | |
| N | 0.418 | ||
| 0 | 63 (95.5%) | 46 (92.0%) | |
| 1 | 0 (0%) | 2 (4.0%) | |
| 2 | 2 (3.0%) | 1 (2.0%) | |
| 3 | 1 (1.5%) | 1 (2.0%) | |
| Stage | 0.418 | ||
| IA | 63 (95.5%) | 46 (92.0%) | |
| IB | 0 (0%) | 2 (4.0%) | |
| IIA | 2 (3.0%) | 1 (2.0%) | |
| IIB | 1 (1.5%) | 1 (2.0%) | |
| Lymph node count | 21 (1-56) | 23 (4-103) | 0.300 |
| Lymph node count | 0.495 | ||
| 0-14 | 15 (22.7%) | 11 (22.0%) | |
| 15-24 | 26 (39.4%) | 24 (30.0%) | |
| 25 or more | 25 (37.9%) | 24 (48.0%) | |
| Margin status | 0.184 | ||
| R0 | 66 (100%) | 48 (96.0%) | |
| R1 | 0 (0%) | 2 (4.0%) |
FIGURE 1Overall 5-year survival in patients with early gastric cancer treated with open and laparoscopic gastrectomy
FIGURE 2Disease-specific 5-year survival in patients with early gastric cancer treated with open and laparoscopic gastrectomy